Cargando…

A Novel Mobile App and Population Management System to Manage Rheumatoid Arthritis Flares: Protocol for a Randomized Controlled Trial

BACKGROUND: Rheumatoid arthritis flares have a profound effect on patients, causing pain and disability. However, flares often occur between regularly scheduled health care provider visits and are, therefore, difficult to monitor and manage. We sought to develop a mobile phone app combined with a po...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Penny, Luo, Dee, Lu, Fengxin, Elias, Josephine S, Landman, Adam B, Michaud, Kaleb D, Lee, Yvonne C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917083/
https://www.ncbi.nlm.nih.gov/pubmed/29643053
http://dx.doi.org/10.2196/resprot.8771
_version_ 1783317125253824512
author Wang, Penny
Luo, Dee
Lu, Fengxin
Elias, Josephine S
Landman, Adam B
Michaud, Kaleb D
Lee, Yvonne C
author_facet Wang, Penny
Luo, Dee
Lu, Fengxin
Elias, Josephine S
Landman, Adam B
Michaud, Kaleb D
Lee, Yvonne C
author_sort Wang, Penny
collection PubMed
description BACKGROUND: Rheumatoid arthritis flares have a profound effect on patients, causing pain and disability. However, flares often occur between regularly scheduled health care provider visits and are, therefore, difficult to monitor and manage. We sought to develop a mobile phone app combined with a population management system to help track RA flares between visits. OBJECTIVE: The objective of this study is to implement the mobile app plus the population management system to monitor rheumatoid arthritis disease activity between scheduled health care provider visits over a period of 6 months. METHODS: This is a randomized controlled trial that lasts for 6 months for each participant. We aim to recruit 190 patients, randomized 50:50 to the intervention group versus the control group. The intervention group will be assigned the mobile app and be prompted to answer daily questionnaires sent to their mobile devices. Both groups will be assigned a population manager, who will communicate with the participants via telephone at 6 weeks and 18 weeks. The population manager will also communicate with the participants in the intervention group if their responses indicate a sustained increase in rheumatoid arthritis disease activity. To assess patient satisfaction, the primary outcomes will be scores on the Treatment Satisfaction Questionnaire for Medication as well as the Perceived Efficacy in Patient-Physician Interactions questionnaire at 6 months. To determine the effect of the mobile app on rheumatoid arthritis disease activity, the primary outcome will be the Clinical Disease Activity Index at 6 months. RESULTS: The trial started in November 2016, and an estimated 2.5 years will be necessary to complete the study. Study results are expected to be published by the end of 2019. CONCLUSIONS: The completion of this study will provide important data regarding the following: (1) the assessment of validated outcome measures to assess rheumatoid arthritis disease activity with a mobile app between routinely scheduled health care provider visits, (2) patient engagement in monitoring their condition, and (3) communication between patients and health care providers through the population management system. TRIAL REGISTRATION: ClinicalTrials.gov NCT02822521, http://clinicaltrials.gov/ct2/show/NCT02822521 (Archived by WebCite at http://www.webcitation.org/6xed3kGPd)
format Online
Article
Text
id pubmed-5917083
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-59170832018-05-03 A Novel Mobile App and Population Management System to Manage Rheumatoid Arthritis Flares: Protocol for a Randomized Controlled Trial Wang, Penny Luo, Dee Lu, Fengxin Elias, Josephine S Landman, Adam B Michaud, Kaleb D Lee, Yvonne C JMIR Res Protoc Protocol BACKGROUND: Rheumatoid arthritis flares have a profound effect on patients, causing pain and disability. However, flares often occur between regularly scheduled health care provider visits and are, therefore, difficult to monitor and manage. We sought to develop a mobile phone app combined with a population management system to help track RA flares between visits. OBJECTIVE: The objective of this study is to implement the mobile app plus the population management system to monitor rheumatoid arthritis disease activity between scheduled health care provider visits over a period of 6 months. METHODS: This is a randomized controlled trial that lasts for 6 months for each participant. We aim to recruit 190 patients, randomized 50:50 to the intervention group versus the control group. The intervention group will be assigned the mobile app and be prompted to answer daily questionnaires sent to their mobile devices. Both groups will be assigned a population manager, who will communicate with the participants via telephone at 6 weeks and 18 weeks. The population manager will also communicate with the participants in the intervention group if their responses indicate a sustained increase in rheumatoid arthritis disease activity. To assess patient satisfaction, the primary outcomes will be scores on the Treatment Satisfaction Questionnaire for Medication as well as the Perceived Efficacy in Patient-Physician Interactions questionnaire at 6 months. To determine the effect of the mobile app on rheumatoid arthritis disease activity, the primary outcome will be the Clinical Disease Activity Index at 6 months. RESULTS: The trial started in November 2016, and an estimated 2.5 years will be necessary to complete the study. Study results are expected to be published by the end of 2019. CONCLUSIONS: The completion of this study will provide important data regarding the following: (1) the assessment of validated outcome measures to assess rheumatoid arthritis disease activity with a mobile app between routinely scheduled health care provider visits, (2) patient engagement in monitoring their condition, and (3) communication between patients and health care providers through the population management system. TRIAL REGISTRATION: ClinicalTrials.gov NCT02822521, http://clinicaltrials.gov/ct2/show/NCT02822521 (Archived by WebCite at http://www.webcitation.org/6xed3kGPd) JMIR Publications 2018-04-11 /pmc/articles/PMC5917083/ /pubmed/29643053 http://dx.doi.org/10.2196/resprot.8771 Text en ©Penny Wang, Dee Luo, Fengxin Lu, Josephine S Elias, Adam B Landman, Kaleb D Michaud, Yvonne C Lee. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 11.04.2018. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.
spellingShingle Protocol
Wang, Penny
Luo, Dee
Lu, Fengxin
Elias, Josephine S
Landman, Adam B
Michaud, Kaleb D
Lee, Yvonne C
A Novel Mobile App and Population Management System to Manage Rheumatoid Arthritis Flares: Protocol for a Randomized Controlled Trial
title A Novel Mobile App and Population Management System to Manage Rheumatoid Arthritis Flares: Protocol for a Randomized Controlled Trial
title_full A Novel Mobile App and Population Management System to Manage Rheumatoid Arthritis Flares: Protocol for a Randomized Controlled Trial
title_fullStr A Novel Mobile App and Population Management System to Manage Rheumatoid Arthritis Flares: Protocol for a Randomized Controlled Trial
title_full_unstemmed A Novel Mobile App and Population Management System to Manage Rheumatoid Arthritis Flares: Protocol for a Randomized Controlled Trial
title_short A Novel Mobile App and Population Management System to Manage Rheumatoid Arthritis Flares: Protocol for a Randomized Controlled Trial
title_sort novel mobile app and population management system to manage rheumatoid arthritis flares: protocol for a randomized controlled trial
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917083/
https://www.ncbi.nlm.nih.gov/pubmed/29643053
http://dx.doi.org/10.2196/resprot.8771
work_keys_str_mv AT wangpenny anovelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT luodee anovelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT lufengxin anovelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT eliasjosephines anovelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT landmanadamb anovelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT michaudkalebd anovelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT leeyvonnec anovelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT wangpenny novelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT luodee novelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT lufengxin novelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT eliasjosephines novelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT landmanadamb novelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT michaudkalebd novelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial
AT leeyvonnec novelmobileappandpopulationmanagementsystemtomanagerheumatoidarthritisflaresprotocolforarandomizedcontrolledtrial